ALVOTECH
NASDAQ: ALVO (Alvotech)
Kemas kini terakhir: 18 jam lalu5.78
0.11 (1.94%)
| Penutupan Terdahulu | 5.67 |
| Jumlah Dagangan | 707,114 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.24 |
| Harga / Jualan (P/S) | 3.51 |
| Julat 52 Minggu |
| Margin Keuntungan | 16.42% |
| Margin Operasi (TTM) | 7.97% |
| EPS Cair (TTM) | 0.370 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 260.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -65.50% |
| Nisbah Semasa (MRQ) | 1.73 |
| Aliran Tunai Operasi (OCF TTM) | -148.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -216.76 M |
| Pulangan Atas Aset (ROA TTM) | 7.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Alvotech | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.43 |
|
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 63.44% |
| % Dimiliki oleh Institusi | 6.44% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |